Corvus Pharmaceuticals Inc (NASDAQ:CRVS)’s traded shares stood at 2.35 million during the last session, with the company’s beta value hitting 1.04. At the close of
Corvus Pharmaceuticals Inc (NASDAQ:CRVS)’s traded shares stood at 1.22 million during the last session, with the company’s beta value hitting 1.04. At the close of
Corvus Pharmaceuticals Inc (NASDAQ:CRVS)’s traded shares stood at 1.27 million during the last session, with the company’s beta value hitting 1.04. At the close of
In the latest trading session,, 0.59 million Corvus Pharmaceuticals Inc (NASDAQ:CRVS) shares changed hands as the company’s beta touched 1.04. With the company’s most recent
In last trading session, Corvus Pharmaceuticals Inc (NASDAQ:CRVS) saw 0.75 million shares changing hands with its beta currently measuring 1.04. Company’s recent per share price
In last trading session, Corvus Pharmaceuticals Inc (NASDAQ:CRVS) saw 1.08 million shares changing hands with its beta currently measuring 1.05. Company’s recent per share price
Corvus Pharmaceuticals Inc (NASDAQ:CRVS) has a beta value of 1.07 and has seen 1.06 million shares traded in the last trading session. The company, currently
Corvus Pharmaceuticals Inc (NASDAQ:CRVS) has a beta value of 1.07 and has seen 1.39 million shares traded in the last trading session. The company, currently
During the last session, Corvus Pharmaceuticals Inc (NASDAQ:CRVS)’s traded shares were 0.65 million, with the beta value of the company hitting 1.04. At the end
Corvus Pharmaceuticals Inc (NASDAQ:CRVS)’s traded shares stood at 1.62 million during the last session, with the company’s beta value hitting 1.12. At the close of
Marketing Sentinel delivers exclusive content, news, articles, and comprehensive coverage of events in the USA and worldwide with a commitment to reliability, objectivity, and timeliness.
© 2024, Powered by Smart TechOne
